Selected article for: "cytokine chemokine storm and infectious disease"
Author: Rui Xiong; Leike Zhang; Shiliang Li; Yuan Sun; Minyi Ding; Yong Wang; Yongliang Zhao; Yan Wu; Weijuan Shang; Xiaming Jiang; Jiwei Shan; Zihao Shen; Yi Tong; Liuxin Xu; Chen Yu; Yingle Liu; Gang Zou; Dimitri Lavillete; Zhenjiang Zhao; Rui Wang; Lili Zhu; Gengfu Xiao; Ke Lan; Honglin Li; Ke Xu
Title: Novel and potent inhibitors targeting DHODH, a rate-limiting enzyme in de novo pyrimidine biosynthesis, are broad-spectrum antiviral against RNA viruses including newly emerged coronavirus SARS-CoV-2
  • Document date: 2020_3_12
    • ID: hq5um68k_28
    Snippet: The results in all provide striking information that DHODH inhibitors are effective in infected animals not only by inhibiting virus replication (Shown in Fig. 3 and Fig. 4) but also by eliminating excessive cytokine/chemokine storm. Usage of DHODHi could finally benefit to advanced disease in late infection. In this study, we applied DHODH inhibitors including a computer-aided designed compound S312 into viral infectious disease. We found that d.....
    Document: The results in all provide striking information that DHODH inhibitors are effective in infected animals not only by inhibiting virus replication (Shown in Fig. 3 and Fig. 4) but also by eliminating excessive cytokine/chemokine storm. Usage of DHODHi could finally benefit to advanced disease in late infection. In this study, we applied DHODH inhibitors including a computer-aided designed compound S312 into viral infectious disease. We found that direct-targeting DHODHi are broad-spectrum antiviral both in cell culture and in vivo. The candidate S312 had further advantage to be used in infected animals with low toxicity and high efficiency.

    Search related documents:
    Co phrase search for related documents
    • advanced disease and cell culture: 1, 2, 3, 4
    • advanced disease and cytokine chemokine storm: 1
    • advanced disease and DHODH inhibitor: 1
    • advanced disease and direct target: 1
    • advanced disease and infectious disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
    • advanced disease and late infection: 1, 2
    • advanced disease and low toxicity: 1
    • broad spectrum and cell culture: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • broad spectrum and DHODH inhibitor: 1, 2, 3
    • broad spectrum and direct target: 1, 2
    • broad spectrum and high efficiency: 1, 2, 3, 4, 5, 6, 7
    • broad spectrum and high efficiency low toxicity: 1
    • broad spectrum and infected animal: 1, 2, 3, 4
    • broad spectrum and infectious disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • broad spectrum and late infection: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • broad spectrum antiviral and DHODH inhibitor: 1, 2
    • broad spectrum antiviral and direct target: 1, 2
    • broad spectrum antiviral and infectious disease: 1, 2, 3, 4
    • broad spectrum antiviral and late infection: 1, 2, 3, 4, 5, 6